New immune cell therapy takes on tough childhood leukemia
NCT ID NCT05105152
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to better recognize and attack leukemia cells. The main goals are to see if the treatment is safe and if the modified cells can be successfully made for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.